medigraphic.com

2015, Number 1

<< Back Next >>

Rev Hosp Jua Mex 2015; 82 (1)

Sustancia P en la inflamación articular

Barbosa-Cobos RE, Ramos-Cervantes MT, De Montesinos-Sampedro A, Rodríguez-Ballesteros DC, García-Moreno-Mutio SL, Jaimes-Santoyo J, Lugo-Zamudio GE, Becerril-Mendoza LT, González-Ramírez LV, Ocharán-Hernández ME, Beltrán-Ramírez O, Toscano-Garibay J

Language: Spanish
References: 29
Page: 49-54
PDF size: 203.40 Kb.


ABSTRACT

P substance (PS) is a neuropeptide, memeber of the tachykinines family that activates the receptor to neurokinin 1 (NKR-1). NKR-1 is a G-protein coupled receptor synthesized in the cellular body of periferic nerves and distributed throughout the entire nervous system. It is also produced by non-neurologic cells such as epithelial cells, macrophages, granulocytes, limphocytes and dendritic cells. PS is a potent mediator of neurogenic inflammation and it is involved in the neuroimmune axis regulating inflammatory reactions of diverse tissues. It has been demonstrated in animal models that levels of PS are increased in synovial liquid, plasma and serum of patients with reumathoid arthritis. In this review, a brief description of the findings suggesting that PS may play a crital role in articular inflammation is presented.


REFERENCES

  1. O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201: 167-80.

  2. Fernandes ES, Schmidhuber SM, Brain SD. Sensory-nervederived neuropeptides: possible therapeutic targets. Handb Exp Pharmacol 2009; 194: 393-416.

  3. Chadwick D, Goode J (edS). Osteoarthritic joint pain. UK: JohnWiley & Sons Ltd;2004.

  4. Brain SD, Cox HM. Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 2006; 147(Suppl. 1): S202-s211.

  5. O’Shaughnessy MC, Vetsika EK, Inglis JJ, Carleson J, Haigh R, Kidd BL, Winyard PG. The effect of substance P on nitric oxide release in a rheumatoid arthritis model. Inflamm Res 2006; 55: 236-40.

  6. Cattaruzza F, Poole DP, Bunnett NW. Arresting inflammation: contributions of plasma membrane and endosomal signalling to neuropeptide-driven inflammatory disease. Biochem Soc Trans 2013; 41: 137-43.

  7. Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in pancreatic cancer. World J Gastroenterol 2014; 20: 2321-34.

  8. Roux BT, Cottrell GS. G protein-coupled receptors: what a difference a ‘partner’ makes. Int J Mol Sci 2014; 15: 1112-42.

  9. Garrett NE, Mapp PI, Cruwys SC, Kidd BL, Blake DR. Role of substance P in inflammatory arthritis. Ann Rheum Dis 1992; 51: 1014-8.

  10. Zhang B, Muneta T, Yagishita K, Sekiya I. Substance P immunoreactive fibers of synovial tissue in patients with anterior cruciate ligament injury. Knee Surg Sports Traumatol Arthrosc 2006; 14: 404-10.

  11. Richardson JD, Vasko MR. Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 2002; 302: 839-45.

  12. Verdrengh M, Tarkowski A. The impact of substance P signalling on the development of experimental staphylococcal sepsis and arthritis. Scand J Immunol 2008; 67: 253-9.

  13. Ramalho R, Soares R, Couto N, Moreira A. Tachykinin receptors antagonism for asthma: a systematic review. BMC Pulm Med 2011; 11: 41.

  14. Vatrella A, Montagnani S, Calabrese C, Parrella R, Pelaia G, Biscione GL, et al. Neuropeptide expression in the airways of COPD patients and smokers with normal lung function. J Biol Regul Homeost Agents 2010; 24: 425-32.

  15. Tavano F, di Mola FF, Latiano A, Palmieri O, Bossa F, Valvano MR. Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on Substance P serum levels. J Crohns Colitis 2012; 6: 563-70.

  16. Peters EM, Ericson ME, Hosoi J, Seiffert K, Hordinsky MK, Ansel JC, et al. Neuropeptide control mechanisms in cutaneous biology: physiological and clinical significance. J Invest Dermatol 2006; 126: 1937-47.

  17. Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation. J Investig Dermatol Symp Proc 2011; 15: 33-9.

  18. Mijouin L, Hillion M, Ramdani Y, Jaouen T, Duclairoir-Poc C, Follet-Gueye ML, et al. Effects of a skin neuropeptide (substance p) on cutaneous microflora. PLoS One 2013; 8: e78773.

  19. Teresiak-Mikolajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus. Postepy Dermatol Alergol 2013; 30: 286-92.

  20. Mantelli F, Micera A, Sacchetti M, Bonini S. Neurogenic inflammation of the ocular surface. Curr Opin Allergy Clin Immunol 2010; 10(5): 498-504.

  21. Kidd BL, Mapp PI, Blake DR, Gibson SJ, Polak JM. Neurogenic influences in arthritis. Ann Rheum Dis 1990; 49: 649-52.

  22. Bulling DG1, Kelly D, Bond S, McQueen DS, Seckl JR. Adjuvant-induced joint inflammation causes very rapid transcription of beta-preprotachykinin and alpha-CGRP genes in innervating sensory ganglia. J Neurochem 2001; 77: 372-82.

  23. Makino A, Sakai A, Ito H, Suzuki H. Involvement of tachykinins and NK1 receptor in the joint inflammation with collagen type II-specific monoclonal antibody-induced arthritis in mice. J Nippon Med Sch 2012; 79: 129-38.

  24. Tanabe T, Otani H, Mishima K, Ogawa R, Inagaki C. Mechanisms of oxyradical production in substance P stimulated rheumatoid synovial cells. Rheumatol Int 1996; 16: 159-67.

  25. Seegers HC, Hood VC, Kidd BL, Cruwys SC, Walsh DA. Enhancement of angiogenesis by endogenous substance P release and neurokinin-1 receptors during neurogenic inflammation. J Pharmacol Exp Ther 2003; 306: 8-12.

  26. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993; 32: 31-5.

  27. Origuchi T, Iwamoto N, Kawashiri SY, Fujikawa K, Aramaki T, Tamai M, et al. Reduction in serum levels of substance P in patients with rheumatoid arthritis by etanercept, a tumor necrosis factor inhibitor. Mod Rheumatol 2011; 21: 244-50.

  28. Grimsholm O, Rantapää-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R416-R426.

  29. Green PG. Gastrin-releasing peptide, substance P and cytokines in rheumatoid arthritis. Arthritis Res Ther 2005; 7: 111-3.




2020     |     www.medigraphic.com